InvestSMART

CSL Limited (ASX: CSL) - Announcements

Current share price for CSL : $202.920 1.62 (0.79%)+

ASX company news and announcements for CSL Limited (CSL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All CSL Limited (CSL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than CSL Limited (CSL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for CSL Limited (CSL)

Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
$97,378 Becoming a substantial holder 18 Oct 2016 9:22AM $104.260 $202.920 risen by 94.63%
$97,378 Appendix 3Y - Change of Director's Interest Notice 14 Oct 2016 3:24PM $105.860 $202.920 risen by 91.69%
$97,378 Appendix Z - Final Director's Interest Notice 14 Oct 2016 9:01AM $104.970 $202.920 risen by 93.31%
$97,378 New Debt Facilities 14 Oct 2016 8:28AM $104.970 $202.920 risen by 93.31%
$97,378 Results of the 2016 AGM 12 Oct 2016 3:32PM $106.250 $202.920 risen by 90.98%
$97,378 Announcement of buy-back - Appendix 3C 12 Oct 2016 2:55PM $106.215 $202.920 risen by 91.05%
$97,378 CEO's AGM Presentation 12 Oct 2016 10:01AM $105.480 $202.920 risen by 92.38%
$97,378 Chairman's Address to Shareholders 12 Oct 2016 10:00AM $105.480 $202.920 risen by 92.38%
$97,378 Appendix 3B 11 Oct 2016 10:46AM $105.620 $202.920 risen by 92.12%
$97,378 Change to Company details 22 Sep 2016 12:09AM $104.190 $202.920 risen by 94.76%
$97,378 Appendix 3B 20 Sep 2016 2:03PM $102.595 $202.920 risen by 97.79%
$97,378 Appendix 4G - Key to Disclosures 9 Sep 2016 8:57AM $103.720 $202.920 risen by 95.64%
$97,378 Notice of Annual General Meeting/Proxy Form 9 Sep 2016 8:55AM $103.720 $202.920 risen by 95.64%
$97,378 Annual Report to shareholders 9 Sep 2016 8:53AM $103.720 $202.920 risen by 95.64%
$97,378 Change of Director's Interest Notice 2 Sep 2016 3:27PM $105.010 $202.920 risen by 93.24%
$97,378 Final share buy-back notice - Appendix 3F 2 Sep 2016 8:25AM $107.300 $202.920 risen by 89.11%
$97,378 Daily share buy-back notice - Appendix 3E 2 Sep 2016 8:25AM $107.300 $202.920 risen by 89.11%
$97,378 Change to Company Details 1 Sep 2016 4:55PM $107.300 $202.920 risen by 89.11%
$97,378 Initial Director's Interest Notice 1 Sep 2016 10:50AM $107.710 $202.920 risen by 88.39%
$97,378 Daily share buy-back notice - Appendix 3E 1 Sep 2016 8:24AM $108.100 $202.920 risen by 87.72%
$97,378 Daily share buy-back notice - Appendix 3E 31 Aug 2016 8:11AM $110.140 $202.920 risen by 84.24%
$97,378 FDA Accepts BLA for Hereditary Angioedema Therapy 30 Aug 2016 9:22AM $108.670 $202.920 risen by 86.73%
$97,378 Daily share buy-back notice - Appendix 3E 30 Aug 2016 8:46AM $108.670 $202.920 risen by 86.73%
$97,378 Appendix 3B 30 Aug 2016 12:01AM $109.810 $202.920 risen by 84.79%
$97,378 Daily share buy-back notice - Appendix 3E 29 Aug 2016 8:19AM $109.050 $202.920 risen by 86.08%

876 - 900 of 1207 results

Page 36 of 49

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.